Significantly lower IL-24 expression predicted poorer prognosis in lung adenocarcinoma (24), breast cancer (25), head and neck squamous cell carcinoma (26), and lymphoma (27, 28). This evidence concerns the gene IL24 and lung adenocarcinoma.